Background: There is currently considerable discussion about the accuracy of blood glucose concentrations determined by personal blood glucose monitoring systems (BGMS). To date, the FDA has allowed new BGMS to demonstrate accuracy in reference to other glucose measurement systems that use the same or similar enzymatic-based methods to determine glucose concentration. These types of reference measurement procedures are only comparative in nature and are subject to the same potential sources of error in measurement and system perturbations as the device under evaluation. It would be ideal to have a completely orthogonal primary method that could serve as a true standard reference measurement procedure for establishing the accuracy of new BGMS.
Methods: An isotope-dilution liquid chromatography/mass spectrometry (ID-UPLC-MRM) assay was developed using (13)C6-glucose as a stable isotope analogue to specifically measure glucose concentration in human plasma, and validated for use against NIST standard reference materials, and against fresh isolates of whole blood and plasma into which exogenous glucose had been spiked. Assay performance was quantified to NIST-traceable dry weight measures for both glucose and (13)C6-glucose.
Results: The newly developed assay method was shown to be rapid, highly specific, sensitive, accurate, and precise for measuring plasma glucose levels. The assay displayed sufficient dynamic range and linearity to measure across the range of both normal and diabetic blood glucose levels. Assay performance was measured to within the same uncertainty levels (<1%) as the NIST definitive method for glucose measurement in human serum.
Conclusions: The newly developed ID UPLC-MRM assay can serve as a validated reference measurement procedure to which new BGMS can be assessed for glucose measurement performance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667352 | PMC |
| http://dx.doi.org/10.1177/1932296815586015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucose Transporter 1 Deficiency Impairs Glucose Metabolism and Barrier Induction in Human Induced Pluripotent Stem Cell-Derived Astrocytes.
J Cell Physiol
January 2025
Department of Pharmaceutical Sciences and Center for Blood-Brain Barrier Research, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Glucose is a major source of energy for the brain. At the blood-brain barrier (BBB), glucose uptake is facilitated by glucose transporter 1 (GLUT1). GLUT1 Deficiency Syndrome (GLUT1DS), a haploinsufficiency affecting SLC2A1, reduces glucose brain uptake.
View Article and Find Full Text PDFThe predictive value of admission blood glucose to serum albumin ratio for futile recanalization after successful interventional recanalization in acute cerebral infarction with large vessel occlusion.
Front Neurol
December 2024
Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Aims: We aim to explore the predictive value of admission blood glucose to serum albumin ratio (AAR) for futile recanalization after successful interventional recanalization of acute cerebral infarction.
Methods: We retrospectively collected the data of patients suffered from acute cerebral infarction due to anterior circulation large vessel occlusion and received successful interventional recanalization from January 2019 to November 2023. Statistical analysis of clinical data was conducted using SPSS 26.
Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study.
Diabetes Metab Syndr Obes
January 2025
Department of Diabetes, Metabolism and Endocrinology, Toho University Graduate School of Medicine, Tokyo, Japan.
Purpose: Imeglimin is a novel oral antidiabetic agent that improves glucose tolerance. This study aimed to investigate the efficacy of combining imeglimin with dipeptidyl peptidase-4 inhibitor (DPP-4i), the most frequently prescribed first-line treatment for patients with type 2 diabetes (T2D) in Japan, to improve glycemic control.
Patients And Methods: Eleven patients with T2D treated with DPP-4i alone (6.
Trends in Total Antioxidant Status and Other Biochemical Parameters in Type 2 Diabetes Mellitus: A Case-control Study.
Curr Diabetes Rev
January 2025
Dept. of Pathology Proficiency Healthcare Diagnostics Laboratory, Al Ain, 97751, United Arab Emirates.
Objectives: Owing to the existing evidence of the implication of oxidative stress in the pathophysiology of type 2 diabetes mellitus (T2DM), the present study aims to investigate the correlation of serum total antioxidant status (TAS) with comorbidities, various biochemical parameters, and duration of T2DM. Various factors contributing to disease prevalence and trends in other biochemical parameters are assessed.
Methods: A retrospective observational study of 246 patients with T2DM whose data were retrieved from the Proficiency Health Diagnostic Lab System in Al Ain.
Health Literacy and Numeracy in Self-monitoring of Capillary Glycemia: A Systematic Review of Mixed Methods.
Curr Diabetes Rev
January 2025
College of Nursing of the University of São Paulo at Ribeirão Preto Campus, Ribeirão Preto, São Paulo, Brasil.
Objective: The aim of this study was to synthesize scientific evidence on the influence of health literacy and numerical knowledge on self-monitoring of capillary blood glucose.
Methods: Adhering to the PRISMA guidelines and the principles of the Joanna Briggs Institute, a comprehensive search was conducted across multiple databases, including CINAHL, Cochrane, Embase, LILACS, PubMed, Scopus, Web of Science, Google Scholar, OPENGREY, and NDLTD. The review included studies published in any language that examined the relationship between HL, numeracy, and SMBG.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!